SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Korábbi kezelés

• Received anti-tumor therapies such as chemotherapy, radiotherapy, biological therapy, targeted therapy, or immunotherapy within 4 weeks before the first dose of the study
• Toxicities caused by previous anticancer therapy were not recovered to CTCAE 5.0 Grade≤1;

Más betegség

• Individuals with a history of GI perforation or fistula, unstable GI bleeding;
• Individuals with a history of severe cardiovascular and cerebrovascular diseases;

Egyéb

• HER2 posotive (IHC 3+ or IHC 2+/ISH +);
• Individuals with Leptomeningeal metastasis or Active brain metastases;
• The researcher determined that there are other situations that are not suitable for participation.

• Age 18 to 75 years old (including boundary values)
• Volunteer to participate in this clinical study and sign informed consent;
• ECOG score 0-1;
• Expected survival ≥3 months;
• Gastric or Gastroesophageal Junction Adenocarcinoma;
• positive CLDN18.2 expression in tumor tissue;
• There is at least one measurable or evaluable lesion that meets the RECIST 1.1 criteria;
• Adequate bone marrow and organ function.